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ABSTRACT
Background: Celiac disease (CD) is an autoimmune disease characterized by immune-
mediated inflammatory damage of the small intestinal mucosa, precipitated by the 
ingestion of gluten-containing foods. Since human leucocyte antigen DQ2 (HLA-DQ2) 
is a marker of nonresponsiveness to hepatits B virus (HBV) vaccine, CD may also be as-
sociated with this nonresponsiveness.
Objectives: The aim of this study was to compare the responses to HBV vaccine between 
children with CD and healthy children. We also investigated the relationship between 
the patients’ responses to hepatitis B vaccine, the clinical presentation of CD, and di-
etary compliance in the patients.
Patients and Methods: We recruited 52 children with CD and 20 age- and sex-matched 
healthy children who received HBV vaccination according to the standard immuniza-
tion schedule. The production of specific antihepatitis B surface antigen (HBsAg) anti-
bodies was evaluated in all patients and control participants. Subjects with less than 
10 IU/L anti-HBs were considered nonresponders to the vaccination.
Results: 31 of the 52 patients (59.6%) were female and 21 (40.4%) were male. The mean 
age of the CD patients was 10.7 ± 4 years (range, 4–18 years). Anti-HBs titers were posi-
tive in 32 (61.5%) patients and negative in 20 (38.5%) patients, while they were positive 
in 18 (90%) of the children in the control group (P < 0.05). We found statistically sig-
nificant differences between negative anti-HBs titers, clinical presentation of CD, and 
dietary compliance in patients with CD (P < 0.05).
Conclusions: Nonresponsiveness to hepatitis B vaccination was more frequently found 
in children with CD than in the control group. Therefore, the response to HBV vaccina-
tion should be investigated in children with CD, and a different immunization sched-
ule may need to be developed. Further, compliance to the prescribed gluten-free diet 
(GFD) may improve the immune response to HBV vaccination in children with CD.
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  Implication for health policy/practice/research/medical education:
Celiac Disease is a common disease. Nonresponsiveness of celiac patients to the HBV vaccine may be give rise to a large 
population of HBV-susceptible individuals. Therefore, a significant public health problem can be occur related to HBV. 
This article can be useful for all health related employees, as well as gastroenterologists and hepatologists.
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1. Background
CD is a lifelong, gluten-sensitive, intestinal 
enteropathy  with  multifactorial  etiology.  The  disease 
provides  an  exciting  model  where  both  genetic  and Hepat Mon. 2011;11(8):634-637
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environmental factors play an important role (1). The 
estimated prevalence of CD in the general population 
of North America and Western Europe is close to 1% (2). 
The first study on CD prevalence in Turkey reported that 
the  prevalence  was  1:115  (3).  Genetic,  environmental, 
and immunological factors may play a role in the 
pathogenesis of the disease. CD is associated with the 
extended  major  histocompatibility  complex  (MHC) 
haplotypes B8, DR3, and DQ2, but most specifically 
with DQ2. In fact, human leucocyte antigen (HLA) DQ2 
is found in 90–95% of celiac patients, and individuals 
lacking  the  DQ2  haplotype  are  generally  positive  for 
DQ8 (4-6). Rostami Nejad et al. found that weight loss 
and constipation appeared to be correlated significantly 
with  CD.  This  atypical  presentation,  especially  the 
correlation with constipation, has received considerably 
less attention in clinical practice than typical forms of 
disease such as diarrhea and malabsorption (7). 
HBV infection is an important global public health 
problem; one-third of the world’s population has been 
infected with HBV, which has caused acute and chronic 
liver disease, cirrhosis, and hepatocellular carcinoma   
(4-6, 8, 9). Hepatitis B vaccines were introduced in the early 
1980s (10). The implementation of mass immunization 
programs,  which  have  been  recommended  by  the 
World Health Organization since 1991, has dramatically 
decreased the incidence of HBV infection among infants, 
children, and adolescents in many countries (5). In our 
country, a routine immunization program was initiated 
by the Ministry of Health in 1998 (9). Protective serum 
titers of anti-HBs (greater than 10 IU/L) develop in 
95–99% of healthy infants, children, and young adults 
who  receive  a  series  of  3  intramuscular  doses  (10).  In 
the healthy population, 4–10% of vaccine recipients fail 
to produce protective levels of antibodies to the HBV 
after standard immunization depending on age and the 
presence of various underlying diseases (4, 8, 11). Many 
nongenetic factors including age, obesity, smoking, drug 
abuse, alcoholism, infections, immunosupression, and 
route  of  vaccination  are  known  to  be  associated  with 
nonresponsiveness (8). Nonresponders are often found 
to carry specific HLA haplotypes including B8, DR3, and 
DQ2 (6). CD may be associated with nonresponsiveness to 
the HBV vaccine since HLA genotypes play an important 
role in nonresponsiveness.
2. Objectives
 The aim of this study was to compare the responses to 
HBV vaccination between children with CD and healthy 
children. We also investigated the relationship between 
the response to the HBV vaccine, clinical presentation of 
CD, and dietary compliance in celiac patients.
3. Patients and Methods
A  total  of  52  patients  who  were  diagnosed  with 
CD and received the HBV vaccine according to the 
standard immunization    schedule  in our pediatric 
gastroenterology  department  were  included  in  the 
study. The inclusion criteria required that subjects must 
have completed HBV vaccination at least 6 months before 
enrolment in this study. Patients who had received any 
drug  treatments  were  not  enrolled  in  the  study.  The 
diagnosis of CD was based on the criteria outlined by 
the European Society for Paediatric Gastroenterology, 
Hepatology, and Nutrition (ESPGHAN) (12). Biopsies of 
the small intestine were performed for all patients, and 
all biopsy specimens were evaluated according to the 
modified  Marsh  criteria  (13).  Atypical  presentation  of 
CD included symptoms such as constipation, dyspepsia, 
abnormal results of liver function tests, and alopecia 
areata,  while  clinical  presentation  of  classical  CD 
included symptoms of malabsorption and failure to 
thrive. The control group was composed of 20 age- and 
sex-matched  healthy  children.  Recombinant  hepatitis 
B vaccine (Engerix B, Glaxo Smith and Kline, Belgium) 
was administered to all study participants, including CD 
patients and healthy controls. All CD patients and control 
subjects  were  examined  to  determine  the  presence 
of HBsAg and HBV core antibody immunoglobulin 
G (anti-HBcIgG), and the quantity of anti-HBs. These 
HBV  markers  were  measured  by  standard  enzyme-
linked  immunosorbent  assay  (ELISA;  Organon  Teknika 
Hepanostika, Holland). Subjects with anti-HBs less than 
10 IU/L were considered nonresponders to the vaccine. 
HBsAg and anti-HBcIgG were negative in all CD patients 
and in the control group. Informed consent was obtained 
from the parents of each child. The study was approved 
by the Ethical Committee of Ataturk University. Statistical 
analyses were carried out using SPSS 12.0.
4. Results
31 of the 52 patients (59.6%) were female, and 21 (40.4%) 
were male. The mean age of the patients with CD was 
10.7 ± 4 years (range, 4–18 years). 38 (73.1%) of the patients 
with CD had typical CD presentation, while 14 (26.9%) 
patients had atypical CD presentation. Among the CD 
patients, 10 (19.2%) had another accompanying disease 
(insulin-dependent diabetes mellitus, 4 [7.6%] patients; 
autoimmune hepatitis, 3 [5.8%] patients; or epilepsy, 3 
[5.8%] patients). 44 (84.6%) CD patients were compliant 
with  the  prescribed  gluten  free  diet  (GFD),  whereas 
8  (15.4%)  were  noncompliant.  Anti-HBs  titers  of  CD 
patients were found to be positive in 32 (61.5%) patients 
and  negative  in  20  (38.5%)  patients,  while  90%  (18/20) 
of control participants had positive anti-HBs titers. 
The anti-HBs positivity in CD patients was significantly 
lower than that of the control participants (P < 0.05). 
The  relationships  between  anti-HBs  titers  and  sex, 
presentation, coexisting disease, and dietary compliance 
in CD patients is summarized in Table.
5. Discussion
Celiac disease, the most common food-sensitive 
enteropathy in humans, is an autoimmune disease Hepat Mon. 2011;11(8):634-637
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affecting primarily the proximal small intestine because 
of a permanent intolerance for dietary gluten (14, 15). 
Genetic, environmental, and immunological factors 
may all play a role in the pathogenesis of CD (3-5). CD 
can  occur  together  with  a  number  of  endocrinologic, 
neurologic, hepatologic, rheumatologic, cardiologic, 
and dermatologic diseases. The frequency of comorbidity 
with autoimmune disorders is estimated to be 10 times 
higher than that in the normal population (4). In our 
study, 10 CD patients (19.2%) had a coexisting disease. 
Vaccination is an efficient and reliable way to protect 
the population from common HBV infections (4). In a 
study perfomed in eastern Turkey, the seroprevalance of 
HBV was found to be 9.4%. Among 1091 school children, 
only 32 had a history of HBV immunization, and the 
overall HBV vaccination rate was very low, at only 2.9%. 
Mothers’  educational  status,  socio-economic  status, 
and number of siblings were 3 important factors that 
contributed to the protection of children from HBV 
in Turkey (16). Furthermore, old age, smoking, obesity, 
and male gender are factors that may predispose an 
individual to be a nonresponder to HBV vaccination (4, 
8). In our study, evaluation of anti-HBs titers revealed that 
anti-HBs negativity was higher in male CD patients than 
in female CD patients (P = 0.0001). A significantly higher 
incidence of nonresponsiveness to HBV vaccination has 
been shown to be related to MHC and HLA-II antigens and 
homozygotes for the alleles HLA-B8, DR3, and DQ2 (4, 5). 
CD is also known to be associated with HLA-II, specifically 
HLA-DQ2 and HLA-DQ8, and it has been demonstrated 
that HLA-II antigens play a role in nonresponsiveness to 
the hepatitis B vaccine (4). It is thought that both HBsAg 
protein fragments and gliadin peptides bind to HLA-DQ2 
molecules, and their competition for HLA-DQ2 binding 
may result in a defective antibody response against the 
recombinant HBsAg vaccine in active CD (5, 8). In our 
study, the response rate of CD patients to HBV vaccination 
was found to be significantly lower than that of patients 
in the control group (P < 0.05). Park et al. (6) demonsrated 
that 53.9% of children with CD did not show a response 
to standard vaccination regimens for HBV; however, the 
response to other childhood vaccines was not impaired, 
supporting the hypothesis that HLA haplotypes may 
play a role in responding to the HBV vaccine. Nemes et 
al. (8) administered the HBV vaccine to 22 prospective CD 
patients just after diagnosis during dietary treatment 
and found that seroconversion after HBV vaccination was 
95.5%. All of these patients carried HLA-DQ2. They then 
further demonstrated that HLA-DQ alleles did not appear 
to have a primary role in nonresponsiveness to the HBV 
vaccine. Ahishali et al. (4) found that 68% of adults with CD 
were responsive to HBV vaccination; this percentage was 
significantly lower than that in the general population 
(90–95%). They also found that 50% of the patients who 
had additional autoimmune disease along with CD were 
nonresponders to the HBV vaccine, emphasizing the 
involvement of genetic factors in the pathogenesis. In 
our  study,  although  anti-HBs  negativity  was  higher  in 
CD patients who had an additional coexisting disease 
than in patients who did not have a coexisting disease, 
this  difference  was  not  statistically  significant.  In 
addition, the 7 CD patients who also had autoimmune 
hepatitis or insulin-dependent diabetes mellitus could 
have been nonresponsive to HBV vaccination because of 
other diseases unrelated to CD. Ertem et al. (11) evaluated 
anti-HBs titers in CD patients and healthy children. 
They  found  that  anti-HBs  negativity  was  significantly 
higher in CD patients than in healthy controls. They 
also demonstrated that response to the HBV vaccine 
in children with CD who were compliant with the GFD 
was not different from that in the healthy population. 
In our study, anti-HBs positivity was significantly higher 
in celiac patients who were compliant to GFD than in 
those who were noncompliant (P < 0.05). These results 
suggest that there may be an important relationship 
between anti-HBs titers and compliance with the GFD. 
Nonresponsiveness of celiac patients to the HBV vaccine 
may represent a significant public health problem. In 
                                           Anti-HBs P value
Negative, No. (%) Positive, No. (%)
Sex 0.0001
Female
Male
4 (12.9)
16 (76.2)
27 (87.1)
5 (23.8)
Presentation 0.008
Typical
Atypical
19 (50)
1 (7.1)
19 (50)
13 (92.2)
Coexisting disease 0.4
Yes
No
5 (50)
15 (35.7)
5 (50)
27 (64.3)
Dietary compliance 0.04
Yes (tTG IgA a: negative) 
No (tTG IgA a: positive) 
14 (31.8)
6 (75)
30 (68.2)
2 (25)
Table. The Relationship between Anti-HBs Titers and Sex, CD Presentation, Coexisting Diseases, and Dietary Compliance in CD Patients
a Abbreviation: tTG IgA, Tissue transglutaminase immunoglobulin AHepat Mon. 2011;11(8):634-637
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fact, there may be a large population of HBV-susceptible 
individuals since there is a high frequency of CD 
worldwide (5). In our country, where the prevalence of 
CD is high, nonresponsiveness to the HBV vaccine in CD 
patients may hinder the immunization of populations 
by national HBV vaccination. Nonresponsiveness to 
the HBV vaccine was higher in children with CD than 
in normal healthy children. Therefore, response to the 
HBV  vaccine  should  be  investigated  in  children  with 
CD, and a different immunization schedule may need 
to be developed. Furthermore, nonresponsiveness to 
the HBV vaccine may be considered a sign of a possible 
undiagnosed celiac disease. Further studies are required 
to enhance the HBV vaccine response in CD patients. 
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